NurExone Biologic (FRA:J90) Research & Development: €2.28 Mil (TTM As of Mar. 2026)


FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.29
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Research & Development?

NurExone Biologic FRA:J90 -8.98% 34 Research & Development is €2.28 Mil as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. NurExone Biologic's Research & Development for the three months ended in Mar. 2026 was €0.55 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €2.28 Mil.

NurExone Biologic  (FRA:J90) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NurExone Biologic Research & Development Related Terms

NurExone Biologic Research & Development Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Research & Development Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.51 1.31 1.41 1.78 2.25

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.60 0.60 0.53 0.55
FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €2.28 Mil mean?
NurExone Biologic (FRA:J90) has a Research & Development of €2.28 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on NurExone Biologic and its competitors.
Is NurExone Biologic's Research & Development too high?
NurExone Biologic's current Research & Development is €2.28 Mil. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Research & Development compare to VRTX and REGN?
NurExone Biologic's Research & Development of €2.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Research & Development is €2.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Research & Development of €2.28 Mil. The current Research & Development is €2.28 Mil. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Research & Development is €2.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price